RAB40A, member RAS oncogene familyGenealiases: RAR2 · RAR2A
Q-omics provides the consensus-scored RAB40A profile across patient tissues and cancer cell-line models. RAB40A expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RAB40A is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, RAB40A RNA expression shows 19,451 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where RAB40A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB40A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB40A survival associations across molecular data types. RAB40A RNA expression shows survival associations in the most cancer types (18), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB40A RNA expression–survival associations across cancer types. High RAB40A expression shows unfavorable associations in KIRC and UVM, but favorable associations in MESO, READ, SKCM and UCS. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RAB40A RNA expression.
This table summarizes RAB40A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RAB40A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB40A shows lower tumor expression in KIRC, LUSC, LUAD and KICH and higher tumor expression in HNSC and READ. The HNSC box plot shows higher RAB40A RNA expression in tumor versus normal tissue (log2 FC = +0.290, t-test p < 0.001).
This table shows molecular features associated with RAB40A in patient tissues and cancer cell lines. In patient samples, RAB40A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB40A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
